Symbols

MEDP

Medpace Holdings·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

High Cash/net Profit Ratio

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MEDP

Medpace Holdings, Inc.

A global full-service clinical contract research organization that provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries

Industry

Life Science Tools and Services

Established Date

02/18/2014

Listing Date

08/11/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

6,200

Fiscal Year Ends

12-31

Website

www.medpace.com

Security Type

Common stock

Office address

5375 Medpace Way, Cincinnati, OH 45227

Business

Introduction

Medpace Holdings, Inc., incorporated in Delaware on February 18, 2014, is one of the world's leading clinical contract research organizations (CROs) focused on providing science-oriented outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company provides full-process clinical development services covering stages I to IV, and has outstanding advantages in therapeutic areas such as oncology, metabolic diseases, cardiology, antiviral and anti-infective (AVAI) and central nervous system (CNS). Medpace operates in all major therapeutic areas and, with its standardized operating model, is committed to providing timely, high-quality and cost-effective clinical trial services to small and medium-sized biopharmaceutical companies, making it a priority partner.

Company Financials

EPS

MEDP has released its 2025 Q4 earnings. EPS was reported at 4.67, versus the expected 4.18, beating expectations. The chart below visualizes how MEDP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MEDP has released its 2025 Q4 earnings report, with revenue of 708.45M, reflecting a YoY change of 32.03%, and net profit of 135.13M, showing a YoY change of 15.48%. The Sankey diagram below clearly presents MEDP's revenue sources and cost distribution.